Clinical Trial Update: Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure [Phase 3]

View source ↗

Summary

Phase 3 pediatric trial evaluating rivaroxaban for thromboprophylaxis after Fontan procedure in children ages 2 to 8, assessing PK/PD, safety, and efficacy; res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Disease
• Single-ventricle Congenital Heart Disease
• Thrombosis

Drugs mentioned

• Xarelto (rivaroxaban) (rivaroxaban)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Thrombosis | Phase 3 | Status: COMPLETED | Results posted: 2022-03-28